Posts by: Anna Tan, RN

Anna Tan, RN

Anna is responsible for the scripting and production of video news content. Her skills as a registered nurse as well as a proven video content creator on YouTube and other social media platforms allow her to create video news reports that are engaging and easy to understand for patients.

October 7, 2015October 7, 2015

National Kidney Foundation Welcomes Kevin Longino as New CEO

News

The National Kidney Foundation (NKF) welcomes its newly-elected Chief Executive Officer (CEO), Kevin Longino, from Greenwich, CT. After a unanimous vote from the Board of Directors, Longino will be transitioning ... Read more

September 30, 2015September 30, 2015

European Commission Approves Fexeric by Keryx Biopharma for Hyperphosphatemia in CKD Patients

News

Keryx Biopharmaceuticals, a biopharmaceutical company focused on products geared towards patients with renal disease and their healthcare providers, is pleased to announce the European Commission has granted Fexeric (ferric citrate coordination complex) ... Read more

September 8, 2015September 8, 2015

Amgen Submits Marketing Authorization Application For IV Etelcalcetide For Secondary Hyperparathyroidism in CKD

News

Amgen announced it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) through the centralized procedure for etelcalcetide (formerly AMG 416) for the treatment of secondary hyperparathyroidism ... Read more

August 28, 2015August 28, 2015

Symic Biomedical Granted $1.5 Million by NIH to Develop Proteoglycan Mimetic Therapy for Vascular Access Failure in ESRD

News

Symic Biomedical, Inc., a company focused on developing therapeutics that offer an exciting and biologically innovative approach to treating disease, announced it received a Phase II SBIR grant from the National ... Read more

August 27, 2015August 28, 2015

Amgen Submits NDA for Etelcalcetide To Treat Secondary Hyperparathyroidism in CKD

News

Biotechnology pioneer, Amgen, recently announced it has submitted a New Drug Application (NDA) to the US Food and Drug Administration for its investigational drug etelcalcetide (formerly known as AMG 416), indicated ... Read more

August 13, 2015August 13, 2015

Ember to Receive $6 Million From Knight Therapeutics For Exclusive Distribution of CKD Drug

News

Leading Canadian speciality pharmaceutical company, Knight Therapeutics, Inc., together with Ember Therapeutics, Inc., a New York-based privately held company specializing in therapies for osteoarthritis, kidney fibrosis and other indications using Bone ... Read more

July 31, 2015August 3, 2015

FDA Begins Review of OPKO’s NDA Application for Rayaldee for CKD-Related SHPT

News

OPKO Health, Inc., a multinational biopharmaceutical and diagnostics company, announced the US Food and Drug Administration (FDA) has begun review of the Company’s New Drug Application (NDA) for calcifediol modified-release capsules, ... Read more

July 24, 2015July 24, 2015

Research and Markets Release CKD Pipeline Analysis

News

Research and Markets recently released a report detailing today’s pipeline therapeutic products for chronic kidney disease (CKD). This irreversible renal condition is more common in geriatric patients, as it results ... Read more

July 16, 2015July 17, 2015

EHRA Presents First ESC Recommendations for CKD and Cardiac Arrythmias

News

A European Heart Rhythm Association (EHRA) paper detailing the first ESC recommendations for patients diagnosed with cardiac arrhythmias and chronic kidney disease (CKD) was presented last month at the EHRA EUROPACE ... Read more